Search Results - Mark Frattini
- Showing 1 - 2 results of 2
-
1
P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHO... by Nicolas Boissel, Patrice Chevallier, Kevin Curran, Gary Schiller, Hongtau Liu, Richard Larson, Daniel J. Deangelo, Jean-Baptiste Mear, Stephan Grupp, André Baruchel, Marina Konopleva, Alexandra Lacroce, Caroline Roudet, Ana Korngold, Katie Newhall, Eric Laille, Daniel Lee, Mark Frattini, Nitin Jain
Published in HemaSphere (2023-08-01)Get full text
Article -
2
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia by Peter G. Maslak, Tao Dao, Yvette Bernal, Suzanne M. Chanel, Rong Zhang, Mark Frattini, Todd Rosenblat, Joseph G. Jurcic, Renier J. Brentjens, Maria E. Arcila, Raajit Rampal, Jae H. Park, Dan Douer, Laura Katz, Nicholas Sarlis, Martin S. Tallman, David A. Scheinberg
Published in Blood Advances (2018-02-01)Get full text
Article
